Join us at ISCIII !!!
Focis on Advanced Therapies in pediatric cancer.
English
Cellular Biotechnology Lab
273 posts
Cellular Biotechnology Lab
@LAB_BIOC
Cellular Biotechnology Lab at ISCIII Pediatric Cancer / Advanced Therapy / Immunotherapy https://t.co/kalE8dtJnL
Madrid - Spain Katılım Nisan 2023
169 Takip Edilen143 Takipçiler
oc
At ESGCT 2025, @Fesisisimo presented our results from a clinical trial of ALOCELYVIR in children with brain tumors, in a strong collaboration with Dr Álvaro Lassaletta and his team at Hospital Niño Jesús.
@APUpablougarte @AFANION_
@SaludISCIII
Català
We are looking for a postdoctoral researcher with solid expertise in tumor immunology to join our group BIOC (ISCIII), dedicated to immuotherapies on pediatric cancer research.
This opportunity is linked to the AECC postdoctoral fellowships.
Feel free to contact us !!
English
Un agradecimiento especial a las asociaciones de pacientes, @APUpablougarte y @AFANION_ , por si continuo apoyo a nuestro grupo y la investigación en nuevos tratamientos para el cáncer infantil
Español
Our group is presenting our latest results at the CICON25 Congress in Utrecht, a meeting with a special focus on immunotherapy of cancer
@SaludISCIII
English
Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial - The Lancet thelancet.com/journals/lance…
English
Cellular Biotechnology Lab retweetledi
Hoy arranca la jornada principal del Encuentro Internacional sobre Terapias Avanzadas, que celebramos en nuestro campus de Majadahonda. @red_terav
Más de 1️⃣0️⃣0️⃣ expertos se reúnen para compartir avances en terapias y salas blancas al servicio de los pacientes.
Español
Cellular Biotechnology Lab retweetledi
El Instituto de Salud Carlos III (ISCIII) acoge un encuentro internacional sobre terapias avanzadas. Organizado por el #IIER, con el apoyo de la Red Española de terapias Avanzadas (Red TERAV+ ISCIII).
isciii.es/documents/d/gu…
@JavierGC280 @l_marinas
Español
Join us May 28 at ISCIII Majadahonda (Madrid, Spain) 🏨for the Workshop on Adoptive Cell Therapies — dive into the latest on CAR-T and adoptive therapies 💉🧬
Free registration via email: workshop.nextgencar@gmail.com
Don't miss out!"
SETGyC@SETGyC
El 28 de mayo se celebra el 🔬 Workshop on Adoptive Cell Therapies en el Campus de Majadahonda del @SaludISCIII para compartir las últimas novedades en terapias celulares adoptivas y CAR-T 💉 📧 ¡Y es totalmente gratuito! Regístrate vía email a workshop.nextgencar@gmail.com
English
Cellular Biotechnology Lab retweetledi
🔬 Workshop on Adoptive Cell Therapies! 🔬
Open scientific workshop on May 28, 2025, hosted at the Majadahonda Campus of ISCIII (Madrid-Spain).
🎟️ Free access — but registration is required via email: workshop.nextgencar@gmail.com
English
Coming soon, see you in Madrid (Majadahonda) !!!
Javier García Castro@JavierGC280
🧬 3rd INTERNATIONAL WORKSHOP on ADVANCED THERAPIES– register! lnkd.in/d2zgCtdu 🏬 We are pleased to host this event at ISCIII, on our Majadahonda campus @SaludISCIII 💡 Cutting-edge science. A must-attend event for professionals in cell & gene therapy manufacturing
English
In the pilot phase, no clinical responses were observed
in 18 patients unselected TILs.
However, when TILs were selected for neoantigen recognition, 3 responses were seen in 39 patients (7.7%).
Pembrolizumab
was added, and 8 objective responses were
seen in 34 patients (23.5%)
English
Osteosarcoma remains a highly aggressive bone malignancy with limited therapeutic options, necessitating novel treatment strategies.
Minireview:
frontiersin.org/journals/immun…
English
Now, AstraZeneca has announced plans to acquire EsoBiotec for up to 925 M€. The deal includes an initial payment of 389 M€, with up to 526 M€ contingent on achieving specific development and regulatory milestones.
managedhealthcareexecutive.com/view/astrazene…
English
The first patient received a single intravenous dose without prior lymphodepletion. After 28 days, their bone marrow showed no detectable cancer, and free light chain levels normalized, with no major side effects reported.
English
EsoBiotec SA has launched a clinical trial for ESO-T01, in vivo BCMA CAR-T therapy for multiple myeloma
ESO-T01 reprograms T cells directly using the ENaBL platform, which uses a viral vector said to be “immune shielded” via the removal of MHC1 and the overexpression of CD47
English
T cell receptor precision editing of regulatory T cells for
celiac disease.
Authors generated gluten- reactive HLA- DQ2.5–restricted CD4+ engineered eTregs.
e Tregs hold therapeutic potential for restoring gluten
tolerance in their mice model.
science.org/doi/epdf/10.11…
English
Cellular Biotechnology Lab retweetledi
La inversión en ciencia es rentable. Barcelona: un ejemplo a seguir 👇
Español
Cellular Biotechnology Lab retweetledi
Hace 20 años que creamos nuestra Fundación. Hoy nos unimos a la UAM para seguir apoyando la investigación, los tratamientos y la formación en Oncología Pediátrica
Siempre agradecido de como me acogieron en el HNJS y los excelentes médicos que conocí y con los que sigo colaborando
FundaciónUAM@fuam_uam
La @UAM_Madrid y @CatedraUAMFOI presentan una cátedra pionera en el ámbito de la #salud infantil, que promoverá la #investigación, formación y divulgación en el campo de las enfermedades #oncohematológicas que afectan a niños y adolescentes. Más Info: fuam.es/noticias/nace-…
Español